Taxol alleviates 2-methoxyestradiol-induced endothelial permeability

Vascular Pharmacology

Volumn 56, Issue 1-2, 2012, Pages 56-63

  Gorshkov, Boris A ^a   Verin, Alexander D ^a   Zemskova, Marina A ^a   Bogatcheva, Natalia V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

2 methoxyestradiol; Barrier dysfunction; Taxol; Tubulin acetylation

Indexed keywords

2 METHOXYESTRADIOL; EVANS BLUE; HEAT SHOCK PROTEIN 27; HISTONE DEACETYLASE 6; PACLITAXEL; SYNAPTOPHYSIN; TUBACIN; TUBULIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG PENETRATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN PULMONARY ARTERY ENDOTHELIAL CELL; LUNG ENDOTHELIUM; LUNG PARENCHYMA; MALE; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; TRANSENDOTHELIAL RESISTANCE; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ACETYLATION; ANILIDES; ANIMALS; CAPILLARY PERMEABILITY; CELLS, CULTURED; DRUG INTERACTIONS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ESTRADIOL; HISTONE DEACETYLASES; HSP27 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; LUNG; MALE; MICE; MICE, INBRED C57BL; MICROTUBULES; MYOSIN LIGHT CHAINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PHOSPHORYLATION; PULMONARY ARTERY; TUBULIN;

EID: 84856238431     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2011.10.002     Document Type: Article

References (36)

1. Baird R.D., Tan D.S., Kaye S.B. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat. Rev. Clin. Oncol. 2010, 7:575-582.
2. Birukova A.A., Birukov K.G., Adyshev D., Usatyuk P., Natarajan V., Garcia J.G., Verin A.D. Involvement of microtubules and Rho pathway in TGF-beta1-induced lung vascular barrier dysfunction. J. Cell. Physiol. 2005, 204:934-947.
3. Birukova A.A., Birukov K.G., Smurova K., Adyshev D., Kaibuchi K., Alieva I., Garcia J.G., Verin A.D. Novel role of microtubules in thrombin-induced endothelial barrier dysfunction. FASEB J. 2004, 18:1879-1890.
4. Birukova A.A., Smurova K., Birukov K.G., Usatyuk P., Liu F., Kaibuchi K., Ricks-Cord A., Natarajan V., Alieva I., Garcia J.G., Verin A.D. Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho-dependent mechanisms. J. Cell. Physiol. 2004, 201:55-70.
5. Bogatcheva N.V., Adyshev D., Mambetsariev B., Moldobaeva N., Verin A.D. Involvement of microtubules, p38, and Rho kinases pathway in 2-methoxyestradiol-induced lung vascular barrier dysfunction. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 292:L487-L499.
6. Bogatcheva N.V., Verin A.D. The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc. Res. 2008, 76:202-207.
7. Bonomi P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert. Rev. Anticancer. Ther. 2007, 7:415-422.
8. Briasoulis E., Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist 2001, 6:153-161.
9. Chen C.H., Lee W.J., Chang T.C., Chen R.J., Chien C.H., Chow S.N. Antiproliferative effects of 2-methoxyestradiol alone and in combination with chemotherapeutic agents on human endometrial cancer cells. Eur. J. Gynaecol. Oncol. 2009, 30:275-280.
10. Cormio G., Di Vagno G., Melilli G.A., Cazzolla A., Di Gesu G., Carriero C., Cramarossa D., Loverro G., Selvaggi L. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J. Chemother. 1999, 11:407-409.
11. Dahut W.L., Lakhani N.J., Gulley J.L., Arlen P.M., Kohn E.C., Kotz H., McNally D., Parr A., Nguyen D., Yang S.X., Steinberg S.M., Venitz J., Sparreboom A., Figg W.D. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther. 2006, 5:22-27.
12. Escuin D., Kline E.R., Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 2005, 65:9021-9028.
13. Gokmen-Polar Y., Escuin D., Walls C.D., Soule S.E., Wang Y., Sanders K.L., Lavallee T.M., Wang M., Guenther B.D., Giannakakou P., Sledge G.W. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res. 2005, 65:9406-9414.
14. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4389-4394.
15. Hammond J.W., Cai D., Verhey K.J. Tubulin modifications and their cellular functions. Curr. Opin. Cell Biol. 2008, 20:71-76.
16. Han G.Z., Liu Z.J., Shimoi K., Zhu B.T. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res. 2005, 65:387-393.
17. James J., Murry D.J., Treston A.M., Storniolo A.M., Sledge G.W., Sidor C., Miller K.D. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest. New Drugs 2007, 25:41-48.
18. Kang S.H., Cho H.T., Devi S., Zhang Z., Escuin D., Liang Z., Mao H., Brat D.J., Olson J.J., Simons J.W., Lavallee T.M., Giannakakou P., Van Meir E.G., Shim H. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 2006, 66:11991-11997.
19. Kirches E., Warich-Kirches M. 2-methoxyestradiol as a potential cytostatic drug in gliomas?. Anticancer Agents Med. Chem. 2009, 9:55-65.
20. Kris M.G., O'Connell J.P., Gralla R.J., Wertheim M.S., Parente R.M., Schiff P.B., Young C.W. Phase I trial of taxol given as a 3-hour infusion every 21days. Cancer Treat. Rep. 1986, 70:605-607.
21. Lee J.S., Gotlieb A.I. Understanding the role of the cytoskeleton in the complex regulation of the endothelial repair. Histol. Histopathol. 2003, 18:879-887.
22. Matei D., Schilder J., Sutton G., Perkins S., Breen T., Quon C., Sidor C. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol. Oncol. 2009, 115:90-96.
23. Mirzapoiazova T., Kolosova I.A., Moreno L., Sammani S., Garcia J.G., Verin A.D. Suppression of endotoxin-induced inflammation by taxol. Eur. Respir. J. 2007, 30:429-435.
24. Moitra J., Sammani S., Garcia J.G. Re-evaluation of Evans Blue dye as a marker of albumin clearance in murine models of acute lung injury. Transl. Res. 2007, 150:253-265.
25. Mueck A.O., Seeger H. 2-Methoxyestradiol-biology and mechanism of action. Steroids 2010, 75:625-631.
26. Palazzo A., Ackerman B., Gundersen G.G. Cell biology: tubulin acetylation and cell motility. Nature 2003, 421:230.
27. Petrache I., Birukova A., Ramirez S.I., Garcia J.G., Verin A.D. The role of the microtubules in tumor necrosis factor-alpha-induced endothelial cell permeability. Am. J. Respir. Cell Mol. Biol. 2003, 28:574-581.
28. Price K.S., Castells M.C. Taxol reactions. Allergy Asthma Proc. 2002, 23:205-208.
29. Rajkumar S.V., Richardson P.G., Lacy M.Q., Dispenzieri A., Greipp P.R., Witzig T.E., Schlossman R., Sidor C.F., Anderson K.C., Gertz M.A. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin. Cancer Res. 2007, 13:6162-6167.
30. Ricker J.L., Chen Z., Yang X.P., Pribluda V.S., Swartz G.M., Van Waes C. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin. Cancer Res. 2004, 10:8665-8673.
31. Saito S., Lasky J.A., Guo W., Nguyen H., Mai A., Danchuk S., Sullivan D.E., Shan B. Pharmacological inhibition of HDAC6 attenuates endothelial barrier dysfunction induced by thrombin. Biochem. Biophys. Res. Commun. 2011, 408:630-634.
32. Sakamoto J., Matsui T., Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer 2009, 12:69-78.
33. Saloustros E., Mavroudis D., Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert. Opin. Pharmacother. 2008, 9:2603-2616.
34. Sweeney C.J., Miller K.D., Sissons S.E., Nozaki S., Heilman D.K., Shen J., Sledge G.W. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001, 61:3369-3372.
35. Verenich S., Gerk P.M. Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol. Pharm. 2010, 7:2030-2039.
36. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R., Van Echo D.A., Von Hoff D.D., Leyland-Jones B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 1990, 8:1263-1268.